TABLE 3.

Methylation differences of HYAL2 between BC cases and controls in Study I stratify by median of age.

Age	CpG sites	Controls median (IQR)	BC cases median (IQR)	OR (95% CI)* per −10% methylation	p-value*
Age ≤ 45 (case = 144 Control = 192)	HYAL2_CpG_1	0.32 (0.28–0.36)	0.32 (0.28–0.37)	0.93 (0.61–1.43)	0.751
	HYAL2_CpG_2	0.23 (0.19–0.27)	0.24 (0.19–0.31)	0.85 (0.59–1.22)	0.370
	HYAL2_CpG_3	0.37 (0.34–0.41)	0.37 (0.33–0.42)	0.97 (0.58–1.61)	0.895
	HYAL2_CpG_4	0.53 (0.48–0.57)	0.54 (0.48–0.57)	0.87 (0.59–1.28)	0.477
Age > 45 (case = 143 Control = 140)	HYAL2_CpG_1	0.34 (0.30–0.37)	0.32 (0.28–0.37)	2.25 (1.04–4.85)	0.039
	HYAL2_CpG_2	0.24 (0.20–0.30)	0.22 (0.16–0.27)	1.98 (1.12–3.51)	0.018
	HYAL2_CpG_3	0.39 (0.35–0.42)	0.37 (0.31–0.41)	2.25 (1.02–4.94)	0.043
	HYAL2_CpG_4	0.54 (0.50–0.59)	0.54 (0.47–0.60)	1.23 (0.67–2.49)	0.452

*Logistic regression, adjusted for age and batches of measurement. BC, breast cancer; HYAL2, hyaluronoglucosaminidase 2 gene; OR, odds ratio; IQR, interquartile range. The bold values indicate p < 0.05.